Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5442001 | 0.96 | TRPV1 (0.55) | TRPV1TRPA1MAPT | |
| SCHEMBL5443102 | 0.95 | TRPV1 (0.56) | TRPV1TRPA1MAPT | |
| SCHEMBL5455549 | 0.94 | TRPV1 (0.56) | TRPV1TRPA1MAPT | |
| SCHEMBL5454289 | 0.94 | TRPV1 (0.55) | TRPV1TRPA1 | |
| SCHEMBL5445649 | 0.94 | TRPV1 (0.55) | TRPV1TRPA1 | |
| SCHEMBL5449461 | 0.90 | TRPV1 (0.52) | TRPV1TRPA1 | |
| SCHEMBL5442067 | 0.87 | TRPV1 (0.55) | TRPV1TRPA1 | |
| SCHEMBL5453975 | 0.85 | TRPV1 (0.47) | TRPV1TRPA1 | |
| SCHEMBL5455053 | 0.82 | LMNA (0.58) | MAPT | |
| SCHEMBL5449040 | 0.82 | TRPV1 (0.70) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | claimed |
| EP-1651636-A1 | SUBSTITUTED HETEROCYCLIC DIARYLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005007646-A1 | SUBSTITUTED HETEROCYCLIC DIARYLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | GPR35, NPY1R, BDKRB1 | TRPV1 402/4885TRPA1 825/4885MAPT 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.